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Introduction: Antiphospholipid syndrome is a multisystem autoimmune disease characterized by arterial and/or
venous thrombosis and persistent presence of antiphospholipid antibodies. It can be a primary disease or
secondary when associated with other autoimmune diseases.
Case presentation: We present a case of a 16-year-old Caucasian boy with a massive arterial and venous
thrombosis in his lower limbs as well as in his central nervous system with clinical symptoms such as headaches
and chorea. He did not present any clinical or laboratory signs of a systemic inflammatory connective tissue disease,
including systemic lupus erythematosus. Based on the clinical picture and results of the diagnostic tests (positive
antibodies against β2-glycoprotein and a high titre of anticardiolipin antibodies) we finally diagnosed primary
antiphospholipid syndrome. During a 9-month follow up after the acute phase of the disease, he was treated with
low-molecular-weight heparin. Neurological symptoms were relieved. Features of recanalization in the vessels of his
lower limbs were observed. After a subsequent 6 months, because of the failure of preventive treatment – an
incident of thrombosis of the vessels of his testis – treatment was modified and heparin was replaced with warfarin.
Conclusion: Although the preventive treatment with warfarin in our patient has continued for 1 year of follow up
without new symptoms, further observation is needed.
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Antiphospholipid syndrome (APS), which is also called
Hughes syndrome, is characterized by symptoms of
thrombosis of the venous, arterial and capillary vessels,
and recurrent miscarriages in combination with auto-
antibodies directed against the proteins that form com-
plexes with phospholipids and participate in the process
of blood coagulation. Antibodies against β2-glycoprotein
(β2-GPI), lupus anticoagulant (LAC) or anticardiolipin
(aCL) antibodies belong to the class of antiphospholipid
(aPL) antibodies. Less frequently, the antibodies can be di-
rected against other antigens such as prothrombin,
phosphatidylserine, thrombin, active C protein, S protein,* Correspondence: e.smolewska@wp.pl
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[1-3]. APS can be primary (pAPS) or secondary (sAPS)
when it is associated with other diseases. APS can be asso-
ciated with systemic diseases of the connective tissue, and
particularly with systemic lupus erythematosus, other
autoimmune diseases such as diabetes mellitus, thyroid
gland inflammation, inflammatory bowel diseases, sarcoid-
osis, viral infections, tumors, compact tumors as well as
lymphoproliferative disorders. The etiology of this syn-
drome has not been explained and associations of the
pathological process with genetic factors (presence of
HLA-DR7, DR4, DQw7, DRw53) and infectious factors
[1,2,4-7] have been studied. According to the revised clas-
sification criteria for APS it can be diagnosed based on
more than one clinical and one serological symptom [8].ed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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agulation tests, such as activated partial thromboplastin
time (APTT), kaolin time or prothrombin time, which
depend on anionic phospholipids. However, the above
antibodies are not detected in approximately 10% to 15%
of patients with typical APS symptoms (seronegative
APS), which can occur during episodes of vascular oc-
clusion, probably due to binding antibodies in the tissues
[8,9]. Clinically, thrombosis most commonly affects the
veins of the lower limbs and is often associated with pul-
monary thrombosis and hypertension. Arterial throm-
bosis commonly involves brain vessels, particularly in
young people (infarcts, migraine headaches, seizures,
disturbances of cognitive functions); it can also involve
the coronary arteries or result in renal vein thrombosis.
Thrombocytopenia belongs to the most common
hematological manifestations of APS [10-17].
Case presentation
A 16-year-old, healthy Caucasian boy, physically active
and practicing sports, began suddenly complaining of a
sharp pain in his left lower limb, which worsened while
walking. The enlarged circumference, reddening and in-
creased temperature of his left lower limb was observed
as well. His history revealed that pain in his lower limbs
and heels, marked fatigue and limited physical activity
occurred as early as 2 weeks before the examination. Ini-
tially, he was hospitalized at the Department of Pediatric
Surgery in a district hospital and deep vein thrombosis
in his femoral vein up to approximately 10cm above the
knee joint space was diagnosed. The results of labora-
tory tests revealed prolonged APTT: 64.7seconds. The
remaining coagulation parameters including D-dimers
were normal. The patient was administered low-
molecular-weight (LMW) heparin (enoxaparin 40mg
daily), diosmin, and compression therapy. Following
discharge from the district hospital, he was admitted to
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* up to values that could not be determined by laboratory methods.days later, due to increasing lower limb edema and
pain; femoral vein thrombosis in his left lower limb was
confirmed. The results of laboratory tests showed
markedly prolonged APTT, up to values that could not
be determined by laboratory methods, and an increased
level of C-reactive protein (Table 1). An intravenous
antibiotic was applied (amoxicillin-clavulanate) and the
dose of LMW heparin was increased (dalteparin 60mg
daily). Compression therapy was continued. However,
no clinical improvement was observed in his left lower
limb after a month’s therapy; pain in his right foot oc-
curred and his right foot was found to be colder. In
addition, no improvement in his left lower limb was ob-
served in a Doppler sonographic examination. On the
right side, a two-phase blood flow with slightly weaker
pulsation at the level of the adductor canal and the
popliteal artery was found in his common femoral ar-
tery as well as in superficial and deep femoral arteries.
Approximately 12cm to 13cm below the knee joint
space, blood flow was growing weaker in his tibial ar-
terial trunks and changed into one-phase flow, with
medium pulsation. Peripherally, further deficiency of
pulsation was noted in the posterior tibial artery (it was
one-phase and characterized by low pulsation); no flow
was detected in the right anterior tibial artery. Consid-
ering the course of the disease with venal and arterial
thrombosis, a suggestion of an autoimmune disease
was put forward. The patient was admitted to the
Department of Pediatric Neurology 7 days later because
of the occurrence of involuntary movements of his
upper and lower left limbs as well as the left part of his
face. Involuntary movements of the kind of hemilateral
chorea involving his upper left limb were observed. A
Doppler examination of his lower limbs was performed
again and signs of deep vein thrombosis were found.
The thrombotic process involved the femoral vein from
the level of approximately 7cm below the peripheral
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left lower limb veins. The lumen of the veins was totally
filled with thrombi, which were 10mm to 11mm thick.
The thrombi were partially organized. No signs of ves-
sel recanalization were found. Thrombosis was not rec-
ognized in the superficial veins. The flow from the limb
was via the patent VSM and the iliac vein (Figures 1
and 2).
Both the deep and superficial venous vessels of his right
lower limb were permeable and without parietal clots. The
vessels were smooth and reacted properly to pressure. The
flow in cervical vessels was assessed as well and it was
found normal in the common internal and external ca-
rotid arteries. The echocardiography revealed normal
structure and function of the heart. Due to persistent
neurological symptoms computed tomography of the pa-
tient’s head was performed. Based on the results, throm-
bosis of the left sigmoid sinus was suspected.
Magnetic resonance angiography was performed in
order to verify the suspected lesions. However, the exam-
ination did not confirm thrombosis in the left sigmoid
sinus. The suspicion of thrombosis of the internal carotid
vein at the level of the skull base was put forward.
The boy was admitted to the Department of Pediatric
Cardiology and Rheumatology for the purpose of
performing further diagnostic studies. Analysis of the
previous diagnostic findings was made and the diagnos-
tic process was broadened according to the suspicion of
a systemic inflammatory connective tissue disease.
In order to exclude a systemic connective tissue dis-
ease including systemic lupus erythematosus, a number
of immunological tests were performed (rheumatoid fac-
tor, lupus erythematosus cell test, antinuclear antibodies,Figure 1 Thrombosis of the left femoral vein.anti-neutrophil cytoplasmic antibodies), however, the re-
sults were negative. In addition, while searching for the
causes of thrombosis, C protein, S protein and homocyst-
eine concentrations were determined and were found to
be within the normal range. No mutation of the allele of
the gene factor V 1691 G-A (V Leiden) was observed.
The patient was GG homozygote (normal sequence).
No mutation in the prothrombin gene allele was found
either. In both tests his deoxyribonucleic acid was iso-
lated using the commercial kit (CHEMAGEN). The
G20210A mutation in the prothrombin gene was
detected using the restriction fragment length poly-
morphism (RFLP) method with the HINDIII enzyme
(Fermentas). The mutation in the factor V Leiden was
determined using the RFLP method with MNLL enzyme
(Fermentas). Because of the fact that thrombosis oc-
curring in the course of the APS was suspected, ap-
propriate diagnostic procedures were performed. The
obtained results are presented in Table 2.
Markedly increased levels of aCL and positive results
for the anti-β2-GPI were noted twice. The patient did
not present any sign, except chorea, suggestive of lupus
erythematosus or any other systemic inflammatory con-
nective tissue disease. Despite negative LAC, pAPS was
diagnosed. He was treated with LMW heparin (dalteparin
15,000IU daily), acetylsalicylic acid at a dose of 75mg daily
and risperidone, according to the neurologist’s suggestion.
After 9 months of therapy, he remained in a good general
condition, and no signs of chorea were observed. However,
he complained of insomnia, troubles with memorizing
and low mental concentration. Recanalization at the level
of the left subpopliteal vein was observed, however, the
superficial femoral vein from the level of approximately
Figure 2 Thrombi in the lumen of the left femoral vein.
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still filled with clots and no flow was observed. Similarly, a
hyperechogenic thrombus was visualized in the distal part
of the internal left carotid vein.
He was admitted to the hospital 6 months later due to
painful testis edema. Ultrasonography confirmed another
episode of venous thrombosis. The treatment was modi-
fied and LMW heparin was replaced with warfarin at the
alternated dose of 5mg and 7.5mg every second day
under international normalized ratio control. After 1.5
years of follow up the therapy with warfarin continues
and he has no clinical symptoms.
Discussion
APS has been considered the most frequent autoimmune
thrombotic state in children. Despite a lot of unknown
data, it has been quite well described in terms of clinical
and laboratory characteristics [2,10,11]. However, there
are scarce reports concerning this disease in young pa-
tients. Ravelli and Martini analyzed 50 cases of pediatricTable 2 Results of laboratory tests for diagnosing antiphosph
Date of test LAC aCL IgM (U/mL) aCL
March 22 2011 No 31.14
N<12
May 6 2011 No 25.86
N<12
Follow
June 22 2012 2.35 0.169
N<1.2 N<0.109
Abbreviations: aCL anticardiolipin, GPI glycoprotein, Ig immunoglobulin, LAC lupus a
SMU and SGU are the standard units for IgM and IgG antibodies anti- β2GPI (antiboAPS and concluded that the course of the disease in chil-
dren was similar to adults with chorea and jugular vein
thrombosis being recognized more frequently in children,
which also occurred in our case [14]. Primary APS is very
rare in pediatrics. The onset of the disease before the age
of 15 has been estimated to occur in only 2.8% of cases.
The occurrence of sAPS in children in the course of sys-
temic lupus erythematosus is more frequent and accounts
for 9% to 14% of cases [1-3,7].
The current criteria for adults are also applicable for
children but are not fully useful. Obstetric problems,
atherosclerosis or the use of contraceptives do not relate
to young patients. However, symptoms that are frequent
in adults but observable also in children such as livedo
reticularis, thrombocytopenia and chorea are not in-
cluded in the criteria [8,10]. One of the indications to
extend the immune system evaluation was chorea
that occurred in our patient. The Ped-APS Registry, a
collaborative project from the European Forum on
Antiphospholipid Antibodies and the Juvenile Systemicolipid syndrome
IgG (U/mL) β2-GPI IgM (SMU) β2-GPI IgG (SGU)
120.0 Not determined Not determined
N<12
14.25 14.25 107.40
N (0–20) N (0–20) N (0–200)
up
0.072 Not determined Not determined
N<0.156
nticoagulant, N normal range.
dies to β2 glycoprotein) using ELISA method.
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Rheumatology European Society, gathers data on APS in
children [11].
A low level of aPL and anti-β2-GPI is found in 7% to
11% of healthy children. A slightly increased level of β2-
GPI is observed in children with atopic dermatitis and
juvenile idiopathic arthritis. A correlation between an in-
creased level of aCL and previous bacterial or viral infec-
tions or vaccination has been proven [4]. In the case of
our patient, levels of both aCL antibodies and anti-β2-
GPI were determined twice and found to be significantly
increased. Despite negative LAC and normal D-dimers
pAPS was diagnosed, and after a year of follow up the
patient’s LAC was positive and his D-dimers were ele-
vated (Table 2) [12].
The manifestation of APS in children is similar to
adults with primary and secondary syndromes. The main
syndrome is thrombosis of veins or arteries. The throm-
bosis episode may be spontaneous or provoked by an in-
jury, operation, venous stasis, use of contraceptive drugs
and so on. In our patient the first incidence of throm-
bosis occurred after a strenuous march. Despite treat-
ment with heparin, arterial thrombosis in his other limb
occurred after a short period of time. LMW heparin is an
efficient and safe alternative to standard anticoagulation
therapy with unfractionated heparin and oral anticoagu-
lants for both treatment and prevention of thrombo-
embolic events in children of varying ages and underlying
disorders. Anticoagulation with heparin followed by oral
anticoagulants is a standard treatment in the event of an
acute venous or arterial thrombosis. However, in infants
and young children resistance to anticoagulation with hep-
arin and vitamin K antagonists, for example warfarin, is
sometimes observed, and doses of heparin and LMW hep-
arin higher than those for adults are required to achieve
the same anticoagulant effect [2,13].
In children, symptoms concerning inferior and superior
vena cava, liver vessels (Budd–Chiari syndrome), heart,
kidneys and skin are recognized less frequently than in
adults but we did not observe them in our patient.
However, neurological complications such as chorea,
migraines, increase of intracranial pressure, psychoses,
depression, epilepsy, Guillain–Barré syndrome, trans-
verse damage of the medulla and optic nerve inflamma-
tion occur relatively frequently in children. Our patient
reported headache, involuntary movements of his face
and his lower limb during the formation of thrombus in
his jugular vein.
Italian researchers conducted a retrospective study
concerning 14 children with pAPS. They found that arter-
ial and venous thrombosis occurred more frequently in
children than in adults and in a greater number of males
in the studied group. The most frequent common symp-
tom was venous thrombosis of lower limb, profound veinsand symptoms from the central nervous system. In four
cases the children developed symptoms of systemic lupus
or Hodgkin’s lymphoma [14,17].
Conclusions
The case of pAPS we described in a 16-year-old boy is a
relatively rare example of this disease in children and ad-
olescents. However, sAPS is diagnosed more and more
frequently. Further observation of vascular lesions and
possible new clinical symptoms seems necessary in our
patient because of the relatively short course of the
disease.
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